ABIVAX is trading at €84.15, down 4.16%, with no confirmed company-specific catalyst reported for the October 1 decline.
- The CAC 40 fell 1.62% and the SBF 120 declined 1.66%.
- A report linked ABIVAX’s earlier-session decline to French debt concerns and Paris market pressure, but this does not establish the cause of the full move.
- The September 30 announcement of seven obefazimod abstracts for UEG Week was prior news; coverage did not connect it to the selloff.